NuvOx Therapeutics filed Amendment No. 2 to its S-1 registration statement for an IPO of 2,860,000 shares at an estimated $6.00-$8.00 per share, seeking a NYSE American listing under 'NUOX'. The clinical-stage biopharma is developing NanO2, an oxygen therapeutic for hypoxia in stroke, GBM, and ARDS, with Phase IIb GBM enrollment completed and Phase Ib/IIb stroke/ARDS trials ongoing. The company has a going-concern opinion, $332k cash as of June 30, 2026, and expects ~$17.4M net proceeds to fund current trials and prepare for a Phase III GBM trial.
Executive Summary
NuvOx Therapeutics filed Amendment No. 2 to its S-1 registration statement for an IPO of 2,860,000 shares at an estimated $6.00-$8.00 per share, seeking a NYSE American listing under 'NUOX'. The clinical-stage biopharma is developing NanO2, an oxygen therapeutic for hypoxia in stroke, GBM, and ARDS, with Phase IIb GBM enrollment completed and Phase Ib/IIb stroke/ARDS trials ongoing. The company has a going-concern opinion, $332k cash as of June 30, 2026, and expects ~$17.4M net proceeds to fund current trials and prepare for a Phase III GBM trial.
Key Facts
- Offering 2,860,000 shares at $6.00-$8.00 per share; estimated net proceeds ~$17.4M at $7.00 midpoint.
- Product candidate NanO2 targets hypoxia in acute ischemic stroke, GBM, and ARDS; no approved products approved for commercial sale.
- Phase IIb GBM trial (93 patients) enrollment completed; Phase IIb stroke trial (23 patients treated) and Phase Ib ARDS trial (15 patients treated) ongoing.
- Independent auditor's report includes a going-concern opinion; accumulated deficit of $42.3M accumulated deficit as of June 30, 2026.
- Cash position of $332k cash as of June 30, 2026; net loss of $6.0M for H1 2026.
- Use of proceeds: ~$5.0M for Phase IIb GBM, $6.0M for Phase II ARDS, $1.0M for Phase III GBM prep, $0.5M for stroke supply, $0.5M for Phase Ib ARDS.
Financial Impact
IPO expected to raise ~$17.4M net proceeds; company has no product revenue and has a going-concern opinion.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001213900-26-108590 |
| Document: ea022525712ex23-1.htm | 0001213900-26-108590 |
| Document: 0001213900-26-108590-index-headers.html | 0001213900-26-108590 |
| Document: 0001213900-26-108590-index.html | 0001213900-26-108590 |
| Document: 0001213900-26-108590.txt | 0001213900-26-108590 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | S-1/A | — | awaiting T+20 | — | — |
Sep 16, 2026 5w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers